Cancer cell proliferation, apoptosis, angiogenesis, invasion, and metastasis are regulated by an interconnecting network of cellular signaling pathways involving extracellular ligands,
transmembrane receptors, intracellular signaling protein kinases, and transcription factors. These intracellular signaling effectors are in turn modulated by multiple factors,
such as epigenetic changes, oncogenic mutations, molecular chaperones, and ubiquitin-proteasome pathways. Insights into these complicated intracellular processes have exposed many
novel cancer targets for which chemotherapeutic agents may be developed.
Most traditional cancer drugs directly interfere with mitosis, DNA synthesis, and repair systems. A new class of agents induces tumor growth retardation (cytostasis) and apoptosis by exploiting aberrant tumor stroma, tumor vasculature, and cellular signaling mechanisms. Their toxicity profile is also significantly different from traditional cancer drugs. Epidermal growth factor receptor (EGFR), and angiogenesis are successful examples of novel drug targets. Unfortunately many cancer therapeutic agents elicit resistance that renders them ineffective and often produces cross-resistance to other drugs.
At Celon Pharma we aim to obtain drugs specific to innovative targets. Our goal is to develop both RNAi and small molecule based therapeutics able to break the cancer cells’ resistance and to improve efficacy of anti-cancer therapy.
Metabolic disorders
Alzheimer’s disease
Most traditional cancer drugs directly interfere with mitosis, DNA synthesis, and repair systems. A new class of agents induces tumor growth retardation (cytostasis) and apoptosis by exploiting aberrant tumor stroma, tumor vasculature, and cellular signaling mechanisms. Their toxicity profile is also significantly different from traditional cancer drugs. Epidermal growth factor receptor (EGFR), and angiogenesis are successful examples of novel drug targets. Unfortunately many cancer therapeutic agents elicit resistance that renders them ineffective and often produces cross-resistance to other drugs.
At Celon Pharma we aim to obtain drugs specific to innovative targets. Our goal is to develop both RNAi and small molecule based therapeutics able to break the cancer cells’ resistance and to improve efficacy of anti-cancer therapy.
Metabolic disordersAlzheimer’s disease
Celon Pharma Ltd
ul. Ogrodowa 2A
05-092 Lomianki, Kielpin
ul. Ogrodowa 2A
05-092 Lomianki, Kielpin
Celon Pharma © 2009 All Rights Reserved.
Designed by GREGMAR
Designed by GREGMAR